Immune profiling leads to implications for immunotherapy for NF1-associated tumorsEurekAlert (press release)Neurofibromatosis type 1 (NF1) — an autosomal dominant disorder affecting approximately one in every 3,500 people — results in dysfunctional n… Continue reading
CBS News |
Immunotherapy holds promise of turning blood into cancer drugs
CBS News “It shows the unbelievable power of your immune system,” said Dr. David Maloney, Fred Hutch’s medical director for cellular immunotherapy who treated Shefveland with a type called CAR–T cells. “We’re talking, really, patients who have no other options … Turning Blood into Living Drugs to Fight CancerWDIO-TV |
Genetic Engineering & Biotechnology News |
Immunotherapy Response Predicted by DNA Repair Deficiencies
Genetic Engineering & Biotechnology News Now, a team of scientists at the Johns Hopkins Bloomberg–Kimmel Institute for Cancer Immunotherapy and other institutions has just reported on their findings of an expanded, three-year clinical trial of 86 patients with colorectal and 11 other kinds of … Gene Mutations Foretell Immunotherapy ResponseThe Scientist |
|
Fibrocell’s gene therapy candidate FCX-013 nabs Rare Pediatric Disease Designation from FDA; shares ahead 9 …
Seeking Alpha Thinly traded nano cap Fibrocell Science (NASDAQ:FCSC) perks up 9% premarket on light volume in response to its announcement that the FDA has granted Rare Pediatric Disease Designation to Orphan Drug-tagged FCX-013, a gene therapy candidate for … Fibrocell Receives Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized SclerodermaGlobeNewswire (press release) Analysts Offer Predictions for Fibrocell Science Inc’s FY2020 Earnings (FCSC)BBNS |
|
Fibrocell’s gene therapy candidate FCX-013 nabs Rare Pediatric Disease Designation from FDA; shares ahead 9 …
Seeking Alpha Thinly traded nano cap Fibrocell Science (NASDAQ:FCSC) perks up 9% premarket on light volume in response to its announcement that the FDA has granted Rare Pediatric Disease Designation to Orphan Drug-tagged FCX-013, a gene therapy candidate for … Fibrocell Receives Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized SclerodermaGlobeNewswire (press release) Analysts Offer Predictions for Fibrocell Science Inc’s FY2020 Earnings (FCSC)BBNS |
Xconomy |
Last Chance for “What’s Hot in Cancer Immunotherapy 2017” Tickets
Xconomy Registration is closing soon for Xconomy’s “What’s Hot in Cancer Immunotherapy 2017.” It’s all happening on Wednesday, June 14, at the Fred Hutchinson Cancer Research Center in Seattle. We have lined up some of the most forward-thinking entrepreneurs … |
Xconomy |
Last Chance for “What’s Hot in Cancer Immunotherapy 2017” Tickets
Xconomy Registration is closing soon for Xconomy’s “What’s Hot in Cancer Immunotherapy 2017.” It’s all happening on Wednesday, June 14, at the Fred Hutchinson Cancer Research Center in Seattle. We have lined up some of the most forward-thinking entrepreneurs … |